ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. (AVBP): 10 pipeline candidates · 2 upcoming catalysts · ~23 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
22.9 months
D/E 0.08 · 0% dilution
Lead: Phase 3
10 candidates
2 upcoming, next in ~607d
N/A
A transparent, data-derived signal for ArriVent BioPharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$62.1M
Quarterly Burn
$41.9M
Runway
22.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| Aarvik ADC program | Preclinical |
| ARR-002 | Preclinical |
| arr-217 | Phase 1 |
| ARR-217 (MRG-007) | Phase 1 |
| egfr-tki inhibitor based on investigator's choice | Phase 3 |
| firmonertinib | Phase 3 |
| furmonertinib | Phase 3 |
| ICP-189 | Phase 1 |
| MRG007 | Phase 1 |
| platinum-based chemotherapy | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
138
Total value held
$954.2M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 4,401,083 | $101.5M |
| infinitum asset management, llc | 4,148,923 | $95.7M |
| hhlr advisors, ltd. | 3,929,117 | $90.6M |
| vanguard capital management llc | 3,057,786 | $70.5M |
| orbimed advisors llc | 3,027,328 | $69.8M |
| fmr llc | 3,016,132 | $69.6M |
| blackrock, inc. | 2,530,301 | $58.4M |
| novo holdings a/s | 1,942,142 | $44.8M |
| vivo capital, llc | 1,771,832 | $40.9M |
| general catalyst group management, llc | 1,494,786 | $34.5M |
Showing top 10 of 138 institutional holders of ArriVent BioPharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ArriVent BioPharma, Inc.'s pipeline?
ArriVent BioPharma, Inc. (AVBP) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ArriVent BioPharma, Inc.'s lead drug candidate?
ArriVent BioPharma, Inc.'s most advanced tracked candidate is Aarvik ADC program (Preclinical) for Cancer (oncology), with an initial focus on solid tumors.
What is ArriVent BioPharma, Inc.'s next catalyst?
ArriVent BioPharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety " — expected February 15, 2028.
What is ArriVent BioPharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ArriVent BioPharma, Inc. has approximately 22.9 months of cash runway.
What is ArriVent BioPharma, Inc.'s market capitalization?
ArriVent BioPharma, Inc.'s market capitalization is approximately $1.4B.
Get the full picture on ArriVent BioPharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.